Adjuvant/neoadjuvant chemoradiation for gastric and pancreatic cancer

Both gastric and pancreatic cancer remain leading causes of cancer death in the United States and worldwide. While surgical resection continues to be required for long-term cure of both these neoplasms, 5-year survival rates remain poor following surgery alone. For both gastric and pancreatic cancer s, studies examining patterns of recurrence following apparently curative r esection repeatedly demonstrate high rates of locoregional relapse. In this setting, the addition of chemoradiation delivered either before or followi ng surgery represents a logical strategy to improve local tumor control and possibly improve survival, Data suggest that 5-fluorouracil-based chemorad iation, when given at sufficient doses, can effectively palliate patients w ith unresectable gastric cancer. Whether this approach improves response an d survival in patients with resectable gastric cancer remains investigation al. Results of ongoing and recently completed trials will provide further i nformation on the utility of 5-fluorouracil-based regimens, as well as the use of other radiation sensitizers, lit the adjuvant setting. lit patients with resectable pancreatic cancer, the primary goal should be to perform a margin-negative pancreaticoduodenectomy. The use of neoadjuvant chemoradiat ion may increase the likelihood of achieving this goal, and this approach i s being investigated.